FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Cervarix | GlaxoSmithKline | Merck | HPV | Gardasil | FDA review

FDA experts support apps for Cervarix, Gardasil

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


In twin votes likely to add considerable force to U.S. marketing efforts for HPV vaccines, an FDA expert panel has voted to back GlaxoSmithKline's long delayed application to market its HPV vaccine Cervarix to women and soon after supported Merck's application to extend the use of Gardasil to males.

Glaxo had originally tried and failed to gain FDA approval for Cervarix back in 2007 but was thwarted by the agency's desire to see more information on potential side effects, particularly a heightened risk of miscarriage. Since that time the pharma giant has gained approvals in more than 100 countries, while biding its time with the FDA. And while the panel concluded that the link between Cervarix and miscarriages is tenuous, the experts suggested a warning to prevent pregnant women from getting the vaccine. The panel vote makes it all but certain that Glaxo will gain final marketing approval from the FDA, opening the door to the world's biggest drug market and finally offering Merck some competition for Gardasil. Glaxo's shares were buoyed by the news.

Merck, meanwhile, is seeking an FDA approval to use its HPV vaccine to guard against genital warts in boys and men. The panel gave Merck its support, but there was widespread agreement that the use of an HPV vaccine for males 9 to 26 offered little protection against cancer, as HPV-related penile and anal cancer cases are extremely rare. The FDA has indicated that any final approval on Gardasil's use in males will require post-marketing safety studies.

- read the story from the Los Angeles Times
- read the report from Reuters 

Related Articles:
FDA weighs in on Gardasil, Cervarix
Gardasil, Cervarix face FDA next month
Glaxo's Cervarix wards off more HPV strains
Glaxo ready to wait for late-stage Cervarix data
Glaxo makes new bid for Cervarix approval
Glaxo once again seeks FDA OK for Cervarix

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about HPV   Gardasil   FDA review   Cervarix   GlaxoSmithKline   Merck  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.